Insider Selling: Xenon Pharmaceuticals (NASDAQ:XENE) CEO Sells 11,269 Shares of Stock

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) CEO Ian Mortimer sold 11,269 shares of the stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $60.11, for a total value of $677,379.59. Following the sale, the chief executive officer directly owned 14,731 shares of the company’s stock, valued at approximately $885,480.41. This represents a 43.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Ian Mortimer also recently made the following trade(s):

• On Monday, March 9th, Ian Mortimer sold 270,000 shares of Xenon Pharmaceuticals stock. The stock was sold at an average price of $60.33, for a total transaction of $16,289,100.00.
• On Friday, January 2nd, Ian Mortimer sold 40,000 shares of Xenon Pharmaceuticals stock. The stock was sold at an average price of $44.43, for a total transaction of $1,777,200.00.

Xenon Pharmaceuticals Stock Down 2.6%

XENE stock traded down $1.57 on Wednesday, reaching $59.04. 5,546,191 shares of the company’s stock were exchanged, compared to its average volume of 1,583,794. The stock has a fifty day moving average of $43.23 and a 200-day moving average of $41.69. Xenon Pharmaceuticals Inc. has a twelve month low of $26.74 and a twelve month high of $63.95. The firm has a market cap of $4.91 billion, a PE ratio of -13.54 and a beta of 0.91.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its earnings results on Thursday, February 26th. The biopharmaceutical company reported ($1.31) EPS for the quarter, missing the consensus estimate of ($1.20) by ($0.11). During the same period in the prior year, the firm posted ($0.84) EPS. On average, equities research analysts predict that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current fiscal year.

Xenon Pharmaceuticals News Summary

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: Phase 3 X‑TOLE2 trial: azetukalner met its goal in focal‑onset seizures and Xenon said it plans an NDA filing in 3Q‑2026 — a clear clinical milestone that supports future revenue potential. XENE Stock Up as Azetukalner Meets Goal in Focal Onset Seizures Study
• Positive Sentiment: Multiple analyst upgrades and higher price targets (Wells Fargo, Wedbush, HC Wainwright, Deutsche Bank and others) increased street conviction and pushed consensus targets materially above prior levels. That analyst momentum typically supports share appreciation. Deutsche Bank Raises XENE Price Target
• Positive Sentiment: Independent analyst commentary (Needham) expects further upside, reinforcing the buy‑side narrative around azetukalner’s market opportunity. Xenon Pharmaceuticals Stock Price Expected to Rise, Needham & Company LLC Analyst Says
• Neutral Sentiment: Earlier reports noted a proposed $500M offering; that story evolved as management and bankers adjusted size and pricing in response to demand and market conditions. The initial notice itself was informational. Xenon Pharmaceuticals announces proposed $500M public share offering
• Negative Sentiment: Upsized public offering priced at $57.00 per share to raise ~ $650M (with a 30‑day option for additional shares). While the cash strengthens the balance sheet and funds registrational/launch activities, the scale of the sale increases near‑term dilution and likely pressured the stock despite positive trial and analyst news. Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering

Institutional Trading of Xenon Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Avoro Capital Advisors LLC raised its holdings in Xenon Pharmaceuticals by 0.5% in the fourth quarter. Avoro Capital Advisors LLC now owns 5,424,444 shares of the biopharmaceutical company’s stock valued at $243,124,000 after acquiring an additional 24,444 shares in the last quarter. Janus Henderson Group PLC grew its holdings in Xenon Pharmaceuticals by 3.6% during the 4th quarter. Janus Henderson Group PLC now owns 4,084,034 shares of the biopharmaceutical company’s stock worth $183,110,000 after acquiring an additional 140,149 shares in the last quarter. Wellington Management Group LLP increased its position in shares of Xenon Pharmaceuticals by 66.0% in the 3rd quarter. Wellington Management Group LLP now owns 3,609,857 shares of the biopharmaceutical company’s stock worth $144,936,000 after purchasing an additional 1,435,096 shares during the last quarter. Braidwell LP increased its position in shares of Xenon Pharmaceuticals by 33.0% in the 2nd quarter. Braidwell LP now owns 3,605,029 shares of the biopharmaceutical company’s stock worth $112,837,000 after purchasing an additional 895,154 shares during the last quarter. Finally, Capital International Investors raised its stake in shares of Xenon Pharmaceuticals by 7.3% in the 4th quarter. Capital International Investors now owns 3,414,959 shares of the biopharmaceutical company’s stock valued at $153,058,000 after purchasing an additional 233,466 shares in the last quarter. Institutional investors own 95.45% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on the company. Wolfe Research initiated coverage on Xenon Pharmaceuticals in a research report on Monday, February 23rd. They set an “outperform” rating and a $60.00 target price on the stock. Bank of America reiterated a “buy” rating on shares of Xenon Pharmaceuticals in a report on Monday. Jefferies Financial Group set a $100.00 target price on shares of Xenon Pharmaceuticals in a research report on Monday. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Xenon Pharmaceuticals from $56.00 to $90.00 and gave the company a “buy” rating in a report on Tuesday. Finally, HC Wainwright increased their price target on shares of Xenon Pharmaceuticals from $53.00 to $74.00 and gave the stock a “buy” rating in a research note on Tuesday. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Xenon Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $71.94.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.